Journal Article

Significance of platelet activation in vascular access survival of haemodialysis patients

Yao‐Cheng Chuang, Jin‐Bor Chen, Lin‐Cheng Yang and Ching‐Yuan Kuo

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 18, issue 5, pages 947-954
Published in print May 2003 | ISSN: 0931-0509
Published online May 2003 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfg056
Significance of platelet activation in vascular access survival of haemodialysis patients

Show Summary Details

Preview

Background. Vascular access failure is the most common cause of morbidity and hospitalization in haemodialysis (HD) patients. Although there are reports that anti‐platelet agents can prevent vascular access thrombosis, the relationship between platelet activation and vascular access failure is not clear. The aim of this study was to investigate the role of platelet activation in recurrent vascular access failure.

Methods. The studied subjects were divided into three groups: group I included 23 HD patients with recurrent vascular access failure (native arteriovenous fistula <2 year survival or synthetic arteriovenous graft <1 year survival), group II included 15 HD patients with longer vascular access survival (>5 year survival) and group III included 10 healthy volunteers as controls. The expression of platelet activation markers (CD62P and fibrinogen receptor) and the numbers of platelet‐derived microparticles were measured and compared between groups.

Results. CD62P‐positive platelets were significantly higher in group I than in both group II (7.3±3.7 vs 3.5±1.3%; P<0.0005) and group III (2.9±0.9%; P<0.00005). Fibrinogen receptor‐positive (PAC‐1‐positive) platelets were also significantly higher in group I than in group II (2.2±2.1 vs 0.9±0.7%; P<0.01) and group III (0.8±0.6%; P<0.01).

Conclusions. A higher level of circulating activated platelets is associated with shorter survival of vascular access in HD patients. The higher level of circulating activated platelets may be a predictor of recurrent vascular access failure. The potential advantageous effects of anti‐platelet therapy on this patient population warrant further investigation.

Keywords: CD62P; haemodialysis; PAC‐1; platelet activation; platelet‐derived microparticles; vascular access survival

Journal Article.  4630 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.